TVTX - Travere Corp Total Debt to Capital

Public company logo of Travere Therapeutics (TVTX)

Risks for Travere Therapeutics (TVTX) are linked to Filspari promotion costs and expensive research, which pressure capital. This price action chart on GURU.Markets captures a leverage ratio of 24.67, highlighting financial stability driven by drug exclusivity and steady cash flow. Business development relies on alliances with universities and global laboratories to support patients.

TVTX: Travere Therapeutics, Inc. Total Debt to Capital 07/04/2022 - 11/01/2026

Analytical breakdowns for Travere Therapeutics

- price and consensus price forecast:
Price Chart Travere Therapeutics, Inc.|TVTX - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Travere Therapeutics|TVTX - Value Adjusted for Debt and Cash
- book capitalization indicators:
Book Value per Share Travere Therapeutics|TVTX - Book Capitalization|Market Value to Book Value Ratio travere.com|TVTX - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Travere Therapeutics|TVTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Travere Therapeutics|TVTX - Company Aggregate Debts|Debt to Book Value Travere Therapeutics|TVTX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Travere Therapeutics|Quick Ratio travere.com
- earnings and valuation multiples information:
TVTX - Net Financial Result
Basic company analysis:Travere Therapeutics, Inc.
Core merchandise of Travere Corp

This ratio serves as a critical filter during position stress-testing, determining the extent of the business's reliance on borrowed funds relative to its equity. By analyzing the trend of the total debt-to-equity ratio, an investor assesses liquidity risk, which for Travere Therapeutics (TVTX) is mitigated by the inelastic demand for Filspari and the ability to exercise pricing power due to its orphan drug status.

Competitor analysis for Travere Therapeutics

Debt to Equity Ardelyx|ProKidney Corp - Aggregate Debt to Equity|Total Debt to Capital AKBA|TVRD (Cara Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital DMAC (DiaMedica Therapeutics)|Total Debt to Capital unicycive.com UNCY|RMTI - Debt to Equity|All Debt to Shareholders' Equity Ratio CVKD (Cadrenal Therapeutics Inc.)|Conduit Pharma (CDT) - Debt to Equity|Total Debt to Equity Ratio Calliditas Therapeutics AB|RNLX (Renalytix PLC) - Total Debt to Capital|Total Debt to Capital ZyVersa